Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTREPID Lead-In: Brazikumab in Moderately to Severely Active Crohn's Disease
NCT03759288Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2018
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of brazikumab in Crohn's disease, sponsored by AstraZeneca. Started Dec 2018; status: terminated.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03759288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759288.